Sign in

Brian Flornes

Independent Director at American Healthcare REIT
Board

About Brian J. Flornes

Independent director of American Healthcare REIT (AHR) since February 2016; age 61; member of the Audit Committee and current chairman of the Nominating & Corporate Governance (NCG) Committee. Former co-founder and CEO of Vintage Senior Living with 30+ years operating, acquiring, developing, and financing senior housing; B.A. (Communication) and M.B.A. from Loyola Marymount University; member of the World Presidents’ Organization. The proxy notes his specialized experience in healthcare real estate and senior housing operations as core credentials for AHR’s board.

Past Roles

OrganizationRoleTenureCommittees/Impact
Vintage Senior LivingCo-Founder; Co-CEO (1998–Jun 2010); CEO (Jun 2010–Sep 2018)1998–2018Led acquisition/development/financing of 8,000+ senior living units across 11 states
Joint Venture with major U.S. pension fund (senior living)JV lead/partnerSince Feb 2006Acquired 19 communities; NAV >2.5x invested capital
AHR Special CommitteeMemberOct 2020–Oct 2021Oversight on special/conflict matters

External Roles

OrganizationRoleTenureNotes
American Senior Housing AssociationMember (past)Not disclosedIndustry association participation
California Assisted Living AssociationBoard member (past)Not disclosedSector advocacy/standards
World Presidents’ OrganizationMemberNot disclosedExecutive leadership network

Board Governance

ItemDetail
IndependenceDetermined independent under NYSE rules; AHR has a majority-independent board; committees (Audit, Compensation, NCG) fully independent
CommitteesAudit Committee (member); NCG Committee (Chair)
Committee activityAudit Committee held 5 meetings in 2024; NCG Committee held 3 meetings in 2024
Board meetings & attendanceBoard held 9 meetings in 2024; each incumbent director attended at least 75% of aggregate Board and committee meetings served
Annual meeting attendanceAll directors attended the most recent annual meeting
Lead independent directorAHR does not maintain a lead independent director (non-management executive sessions are presided over by the non-executive Chair)
NCG Chair start date (note)Director bio states NCG Chair since Oct 2021; committee section states since June 2023 (proxy contains both references)
Governance policiesCorporate Governance Guidelines; Code of Ethics; Whistleblower; Insider Trading Policy; Clawback; Related Party Transactions Policy
Conflicts oversightNCG oversees conflicts and related-party matters; directors with interests recuse from related-party votes

Fixed Compensation (Director pay)

Element2024 Amount
Fees Earned or Paid in Cash$102,500 (reflects committee roles)
All Other Compensation$21,923 (distributions on stock awards)
Total Director Compensation$316,582 (cash + equity fair value + distributions)

Director cash fee schedule (2024): Audit Committee: Chair $20,000; Member $5,000. Compensation Committee: Chair $12,500. Nominating & Corporate Governance Committee: Chair $12,500. Lead Independent Director: $100,000. (Independent directors reimbursed for meeting expenses.)

Performance Compensation (Equity and vesting)

Grant/InstrumentGrant DateShares/UnitsGrant-Date Fair ValueVestingNotes
Listing Equity Award (restricted stock)Feb 9, 20247,407 shares (to each non-employee director other than CEO/Director Prosky)Included in 2024 “Stock Awards” $192,15925% on each of the first four anniversaries of 2/9/2024 (service-based)Director equity aligns with shareholders; no performance-based director equity disclosed
Nonvested restricted common stock (as of 12/31/2024)11,017 sharesAggregate nonvested shares held by each non-employee director, incl. Mr. Flornes

Notes: AHR’s executive PSU program uses 3-year relative TSR vs. a healthcare REIT peer set; no performance-conditioned equity is disclosed for directors. Hedging and pledging of AHR securities are prohibited by policy.

Other Directorships & Interlocks

CategoryDetail
Current public company boardsNone disclosed for Mr. Flornes
Prior public company boardsNone disclosed for Mr. Flornes
Non-profit/industry boardsCalifornia Assisted Living Association (past); American Senior Housing Association member
Interlocks with competitors/suppliers/customersNone disclosed

Expertise & Qualifications

  • Senior housing operations, real estate acquisition/development/financing, and healthcare real estate domain expertise (30+ years).
  • Education: B.A. (Communication) and M.B.A., Loyola Marymount University.
  • Executive network: World Presidents’ Organization.

Equity Ownership

MetricValue
Beneficial ownership (common) as of Mar 27, 202527,384 shares (<1.0%)
OP UnitsNone
Shares pledgedNone of the disclosed shares have been pledged as security
Ownership guidelinesCorporate Governance Guidelines set minimum stock ownership requirements for directors (specific multiples not disclosed)
Hedging/pledging policyHedging and pledging of AHR securities prohibited for directors/officers

Governance Assessment

  • Strengths: Independent director with sector-operating depth; chairs NCG (conflict oversight, board refreshment, ESG oversight) and serves on Audit, supporting risk/control oversight. Board/committee independence, clawback policy, and anti-hedging/pledging strengthen alignment and oversight.
  • Attendance/engagement: Board met 9 times in 2024 and Audit/NCG met 5/3 times; all incumbents met at least the 75% attendance threshold and attended the annual meeting—baseline engagement satisfied (individual attendance rates not disclosed).
  • Compensation alignment: 2024 director pay mix tilted to equity (service-vested restricted stock) with multi-year vesting; cash fees reflect committee responsibilities (NCG Chair + Audit member). No director performance-conditioned equity disclosed, which is typical in REITs.
  • Shareholder signals (director elections): Notable withhold in 2024 (For: 37,035,533; Withheld: 36,910,722), improving in 2025 (For: 100,685,107; Withheld: 16,587,419), but still among higher withholds—an investor-sentiment flag to monitor.
  • Say-on-pay support (company-wide): Advisory say-on-pay approved—2024 meeting For: 71,399,556 vs. Against: 1,871,807; 2025 meeting For: 109,297,003 vs. Against: 7,525,316—broad support for pay program.
  • Conflicts/related-party: No related-party transactions disclosed involving Mr. Flornes; RPT oversight sits with NCG with recusal requirements; directors were subject to IPO-related lock-ups in 2024.
  • RED FLAGS: Elevated director withhold in 2024 (improved in 2025 but remains higher than peers); minor inconsistency in proxy regarding NCG chair start date (Oct 2021 vs. June 2023). Monitor future votes and disclosures for clarity.

Appendix: Director Election Vote Detail (Signal Tracking)

YearForWithheldBroker Non-Votes
2024 Annual Meeting (Nov 7, 2024)37,035,533 36,910,722 33,651,003
2025 Annual Meeting (Jun 25, 2025)100,685,107 16,587,419 22,564,319